Howard L. Kaufman, MD | Authors


Dr. Kaufman Discusses Durable Responses to Avelumab in Merkel Cell Carcinoma

May 18, 2017

Howard L. Kaufman, MD, a surgical oncologist at Rutgers Cancer Institute of New Jersey, discusses a study which showed further durable responses to avelumab (Bavencio) in patients with merkel cell carcinoma who progressed after chemotherapy.

Is Precision Immunology Possible?

April 09, 2016

Kaufman recently coined the term "precision immunology" to describe the use of host, immune system and tumor factors as biomarkers to select immunotherapy approaches. But, are we ready to integrate precision immunology into clinical practice?